Informazioni generali
  • Categoria della malattia Cancro della tiroide (BASEC)
  • Stato di reclutamento reclutamento non ancora iniziato (BASEC/ICTRP)
  • Luogo dello studio
    Berna
    (BASEC)
  • Responsabile dello studio Urs Borner urs.borner@insel.ch (BASEC)
  • Fonte dati BASEC: Importato da 08.08.2025 ICTRP: N/A
  • Ultimo aggiornamento 08.08.2025 14:55
HumRes66929 | SNCTP000006425 | BASEC2025-D0004

Safety and feasibility of ultrasound-assisted non-invasive measurement of thyroid compressibility in patients scheduled for surgical removal.

  • Categoria della malattia Cancro della tiroide (BASEC)
  • Stato di reclutamento reclutamento non ancora iniziato (BASEC/ICTRP)
  • Luogo dello studio
    Berna
    (BASEC)
  • Responsabile dello studio Urs Borner urs.borner@insel.ch (BASEC)
  • Fonte dati BASEC: Importato da 08.08.2025 ICTRP: N/A
  • Ultimo aggiornamento 08.08.2025 14:55

Descrizione riassuntiva dello studio

During their visit for surgical planning, we will conduct an examination using the medical device (manufactured by Compremium) on the patients included in the study. The device is based on ultrasound technology coupled with a pressure sensor, providing a quick, non-invasive, and painless way to see what is happening inside the body. Five consecutive measurements will be performed by a physician. The ultrasound examination will be conducted while lying down and will last three minutes. During the measurement, an ascending pressure will be applied to the neck, comparable to the pressure experienced when you press your hand flat against the neck. This way, the degree of compression of the nodule will be measured. Although the measurement should not cause pain, patients will be asked to rate any discomfort felt immediately after the procedure on a scale from 0 (no pain) to 10 (worst imaginable pain). The feasibility of the procedure will also be assessed by the physicians using two questionnaires: a usability questionnaire for each participant and general feedback at the end of the study. The safety of the device will be evaluated by recording all issues (e.g., device failures, side effects, or serious problems) and their frequency. Physicians will also be asked to report any new risks that arise from using the device. One to six months later, patients will return to the hospital for their surgery, and we will use the final diagnosis after analyzing the removed tissue to assess whether the compressibility of the thyroid nodule could be used in the future to better predict malignancy and avoid unnecessary surgeries. The study will be conducted with approximately 30 patients and should last a maximum of 18 months.

(BASEC)

Intervento studiato

This clinical study will be conducted on patients who have received a Bethesda IV cytopathological diagnosis of a thyroid nodule from the endocrinology outpatient clinic and are scheduled for surgical removal. During this study, patients will receive standard medical care (examination and treatment), regardless of the results of the thyroid examination with the medical device. The measurement of nodule compressibility with the medical device will be performed by a physician on each study participant. Under ultrasound and real-time pressure measurement, the nodule of interest will be localized and gradually compressed by the examiner using the CP probe and feedback on the extrinsically applied pressure. The measurement process will be repeated five times in a row for each patient to increase robustness. A cut video of the ultrasound image and the simultaneous pressure values during the compression process will be automatically recorded. The degree of compression is called CP Value and could indicate whether the nodule is cancerous. The obtained results will be compared with postoperative histopathological analyses.

(BASEC)

Malattie studiate

Thyroid cancer

(BASEC)

Criteri di partecipazione
- Patients over 18 years old - Patients with a thyroid nodule - Patients with a Bethesda IV cytopathological diagnosis of this nodule - Patients scheduled for surgery after a standard diagnosis - Written documented consent (informed consent) (BASEC)

Criteri di esclusione
- Non-intact skin at the measurement site - BMI > 35 kg/m² - Patients unable to provide informed consent - Pregnant or breastfeeding women (BASEC)

Luogo dello studio

Berna

(BASEC)

non disponibile

Sponsor

Inselspital

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

Urs Borner

+41 31 632 4174

urs.borner@insel.ch

Inselspital

(BASEC)

Informazioni scientifiche

non disponibile

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione d'etica Berna

(BASEC)

Data di approvazione del comitato etico

28.05.2025

(BASEC)


ID di studio ICTRP
non disponibile

Titolo ufficiale (approvato dal comitato etico)
SAFETY AND FEASIBILITY OF ULTRASOUND-ASSISTED NON-INVASIVE MEASUREMENT OF COMPRESSIBILITY OF THE THYROID GLAND IN PATIENTS SCHEDULED FOR SURGICAL REMOVAL (CPMX-THYR) (BASEC)

Titolo accademico
non disponibile

Titolo pubblico
non disponibile

Malattie studiate
non disponibile

Intervento studiato
non disponibile

Tipo di studio
non disponibile

Disegno dello studio
non disponibile

Criteri di inclusione/esclusione
non disponibile

non disponibile

Endpoint primari e secondari
non disponibile

non disponibile

Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
non disponibile

Contatti aggiuntivi
non disponibile

ID secondari
non disponibile

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
non disponibile

Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile